CY1124297T1 - Ορολογικη εξεταση για τον ελεγχο της θεραπειας καρκινωματος θετικου σε hpv16 - Google Patents

Ορολογικη εξεταση για τον ελεγχο της θεραπειας καρκινωματος θετικου σε hpv16

Info

Publication number
CY1124297T1
CY1124297T1 CY20211100609T CY211100609T CY1124297T1 CY 1124297 T1 CY1124297 T1 CY 1124297T1 CY 20211100609 T CY20211100609 T CY 20211100609T CY 211100609 T CY211100609 T CY 211100609T CY 1124297 T1 CY1124297 T1 CY 1124297T1
Authority
CY
Cyprus
Prior art keywords
positive carcinoma
treatment monitoring
serological test
treatment
hpv16 positive
Prior art date
Application number
CY20211100609T
Other languages
English (en)
Inventor
Ralf Hilfrich
Original Assignee
Abviris Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abviris Deutschland Gmbh filed Critical Abviris Deutschland Gmbh
Publication of CY1124297T1 publication Critical patent/CY1124297T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
    • C07K16/084—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • C12N5/12—Fused cells, e.g. hybridomas
    • C12N5/16—Animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20023—Virus like particles [VLP]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αφορά σε μέθοδο για τον έλεγχο της θεραπείας καρκινώματος θετικού σε HPV16, σε ένα αντίσωμα για χρήση στην αντίστοιχη διαγνωστική μέθοδο, καθώς επίσης και σε εξέταση για εκτέλεση της μεθόδου, ειδικότερα, η παρούσα εφεύρεση αφορά σε ορολογική μέθοδο για την παρακολούθηση της ανάπτυξης του αριθμού αντισωμάτων στα δείγματα, τα οποία λήφθηκαν από έναν ασθενή πριν και μετά τη θεραπεία καρκινώματος θετικού σε HPV 16 κατά τη διάρκεια προκαθορισμένης χρονικής περιόδου, επιπλέον, η εφεύρεση προβλέπει ανοσολογική εξέταση υπό τη μορφή συλλογής, με την οποία μπορεί να εκτελείται η μέθοδος σύμφωνα με την εφεύρεση.
CY20211100609T 2016-12-13 2021-07-06 Ορολογικη εξεταση για τον ελεγχο της θεραπειας καρκινωματος θετικου σε hpv16 CY1124297T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102016124171.7A DE102016124171A1 (de) 2016-12-13 2016-12-13 Serologischer Test zur Therapiekontrolle von HPV16 positiven Karzinomen
PCT/EP2017/082506 WO2018108957A1 (en) 2016-12-13 2017-12-13 Serologic test for therapy control of hpv16 positive carcinoma

Publications (1)

Publication Number Publication Date
CY1124297T1 true CY1124297T1 (el) 2022-07-22

Family

ID=61027644

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100609T CY1124297T1 (el) 2016-12-13 2021-07-06 Ορολογικη εξεταση για τον ελεγχο της θεραπειας καρκινωματος θετικου σε hpv16

Country Status (21)

Country Link
US (2) US10852303B2 (el)
EP (1) EP3384292B1 (el)
JP (2) JP7329244B2 (el)
KR (1) KR102433541B1 (el)
CN (1) CN110073219B (el)
BR (1) BR112019011681A2 (el)
CA (1) CA3045729A1 (el)
CY (1) CY1124297T1 (el)
DE (1) DE102016124171A1 (el)
DK (1) DK3384292T3 (el)
ES (1) ES2880489T3 (el)
HR (1) HRP20211080T1 (el)
HU (1) HUE054969T2 (el)
LT (1) LT3384292T (el)
PL (1) PL3384292T3 (el)
PT (1) PT3384292T (el)
RS (1) RS62135B1 (el)
RU (1) RU2757629C2 (el)
SI (1) SI3384292T1 (el)
WO (1) WO2018108957A1 (el)
ZA (1) ZA201804516B (el)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102022127779A1 (de) 2022-10-20 2024-04-25 Ralf Hilfrich Serologischer Test zum Nachweis von Antikörpern gegen HPV und Testkit

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8062642B1 (en) * 1993-03-09 2011-11-22 University Of Rochester Production of papillomavirus capsid protein and virus-like particles
US20020193565A1 (en) * 1998-03-27 2002-12-19 Stanley Margaret Anne Antigen preparation and use
WO2003093511A1 (en) * 2002-04-30 2003-11-13 Merck & Co., Inc. Human papillomavirus multiplexed assay
CN101245099A (zh) * 2007-02-14 2008-08-20 马润林 重组人乳头瘤病毒l1衣壳蛋白的氨基酸序列及其应用
WO2010118424A2 (en) * 2009-04-10 2010-10-14 The Johns Hopkins University Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines
DE102010061028A1 (de) * 2010-12-03 2012-06-06 Ralf Hilfrich Schnelltest zum qualitativen und/oder quantitativen Bestimmen von Körperflüssigkeit enthaltenen Antikörpern gegen humane Papillomviren sowie Vorrichtung zum Durchführen des Schnelltests
DE102011053741A1 (de) * 2011-09-19 2013-03-21 Ralf Hilfrich Verfahren zum Überprüfen der Selbstheilung durch das Immunsystem eines mit humanen Papillomviren infizierten Menschen

Also Published As

Publication number Publication date
US20200408768A1 (en) 2020-12-31
EP3384292B1 (en) 2021-04-21
DK3384292T3 (da) 2021-06-28
US11506667B2 (en) 2022-11-22
RU2019121882A (ru) 2021-01-15
CN110073219A (zh) 2019-07-30
ZA201804516B (en) 2019-04-24
JP2023029377A (ja) 2023-03-03
BR112019011681A2 (pt) 2019-10-15
RU2757629C2 (ru) 2021-10-19
EP3384292A1 (en) 2018-10-10
WO2018108957A1 (en) 2018-06-21
PT3384292T (pt) 2021-07-22
US10852303B2 (en) 2020-12-01
ES2880489T3 (es) 2021-11-24
JP2020501162A (ja) 2020-01-16
KR20190097155A (ko) 2019-08-20
CN110073219B (zh) 2023-09-05
HUE054969T2 (hu) 2021-10-28
KR102433541B1 (ko) 2022-08-18
HRP20211080T1 (hr) 2021-10-01
CA3045729A1 (en) 2018-06-21
RS62135B1 (sr) 2021-08-31
LT3384292T (lt) 2021-07-26
PL3384292T3 (pl) 2021-10-25
RU2019121882A3 (el) 2021-04-09
SI3384292T1 (sl) 2021-08-31
US20190113516A1 (en) 2019-04-18
DE102016124171A1 (de) 2018-06-14
JP7329244B2 (ja) 2023-08-18

Similar Documents

Publication Publication Date Title
CO2019001111A2 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
JP1754773S (ja) サンプル採取器具
BR112018000696A2 (pt) ?anticorpo, métodos para reduzir e para aumentar a afinidade de ligação de um anticorpo que se liga ao cd3 humano, para tratar e para diagnosticar uma doença, para produzir um anticorpo e para detectar a presença de antígeno de cd3, construto de ácido nucleico, vetor de expressão, célula hospedeira, composição, e, kit?
MX2017007617A (es) Aparato y metodos de prueba para biomarcador cardiaco st2.
EA201590025A1 (ru) Нехирургический способ лечения катаракты
EA201690213A1 (ru) Композиции и способ лечения связанных с комплементом состояний
BR112016014010A2 (pt) métodos para detectar anticorpos contra vírus da febre suína clássica tipo selvagem (csfv), para diferenciação entre animais infectados com csfv tipo selvagem e animais que foram vacinados contra csfv e para controlar uma infecção com csfv tipo selvagem, kit de teste de diagnóstico, e, uso de um carreador
TR201907802T4 (tr) Kuantum kapasitans algılama.
EA201690796A1 (ru) Способ диагностики первичного гиперальдостеронизма
BR112014026440A8 (pt) análises, métodos e aparelhos para avaliação de disrupção de rna.
EA201700208A1 (ru) Способ и устройство для обнаружения малярии
CY1124297T1 (el) Ορολογικη εξεταση για τον ελεγχο της θεραπειας καρκινωματος θετικου σε hpv16
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer
MY181007A (en) Scale drop disease (sdd) causative virus and derivatives thereof
BR112016002709A2 (pt) queratinas como biomarcadores para câncer cervical e sobrevivência
EA201692071A1 (ru) Иммуноанализ и антитела для обнаружения хромогранина а
WO2018026969A3 (en) Plazomicin antibodies and methods of use
MX2020005562A (es) Anticuerpos anti-pd-l1 y métodos para utilizarlos para la detección de pd-l1.
MX2016017136A (es) Composiciones y metodos para detectar pegivirus 2 de humano (hpgv-2).
UY36431A (es) Anticuerpos monoclonales específicos para el antígeno m del virus metapneumovirus humano (hmpv), producidos y secretados por hibridomas celulares, útiles para la detección y el diagnóstico de la infección causada por hmpv
RU2013131721A (ru) Способ прогнозирования нейросифилиса
PL401502A1 (pl) Epitop i jego zastosowanie
RU2013151981A (ru) Способ определения типа психики индивидуума
RU2012134260A (ru) Иммуноцитохимический способ оценки реакции бласттрансформации лимфоцитов (рбтл) при стимуляции их фитогемагглютинином (фга)
WO2020132494A3 (en) Methods for prognosing, diagnosing, and treating gastric cancer